Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

BACKGROUND: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Baraniak, Ilona, Gomes, Ariane C., Sodi, Isabella, Langstone, Toby, Rothwell, Emily, Atkinson, Claire, Pichon, Sylvie, Piras-Douce, Fabienne, Griffiths, Paul D., Reeves, Matthew B.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921368/
https://ncbi.nlm.nih.gov/pubmed/31735553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados